Literature DB >> 20299790

Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

M Fareed K Suri1, Kazumasa Yamagishi, Nena Aleksic, Peter J Hannan, Aaron R Folsom.   

Abstract

BACKGROUND AND
OBJECTIVE: The role of hemostatic factor levels in cerebral infarction remains uncertain. We studied the association of levels of several under-studied hemostatic factors with ischemic stroke in a population-based cohort.
METHODS: The Atherosclerosis Risk in Communities (ARIC) study includes 15,792 individuals aged 45-54 years at intake. Hemostatic factors II, V, IX, X, XI, XII, plasminogen and alpha(2)-antiplasmin were measured on frozen citrate plasma samples from 1990 to 1992. A case-cohort design was used, including all incident ischemic strokes (n = 89) over a median of 7.5 years and a stratified cohort random sample (n = 412). To determine the association of hemostatic factors with incident ischemic stroke, we computed hazard ratios (HRs) using multivariate proportional hazard regression analyses adjusted for demographic and other cardiovascular risk factors.
RESULTS: The cohort random sample had a mean age (SD) of 56.9 (5.4) years and 42% were men. The age-, sex- and race-adjusted HRs for highest versus lowest quartiles were: factor XI (2.74, 95% CI 1.42-5.29), factor IX (1.92, 95% CI 0.99-3.73), and alpha(2)-antiplasmin (2.24, 95% CI 1.16-4.33). Correspondingly, the HRs of ischemic stroke per SD increment of factors XI, IX, and alpha(2)-antiplasmin were 1.64, 1.46 and 1.52, respectively (all p < 0.05). After multivariate adjustment including other clinical variables, the standardized HR remained significant for factor XI (1.50, 95% CI 1.10-2.05), but no other factor.
CONCLUSION: A greater level of factor XI was associated with an increased risk of ischemic stroke. Higher factor XI levels might help identify patients at elevated ischemic stroke risk. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299790      PMCID: PMC2865476          DOI: 10.1159/000297966

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  26 in total

1.  Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.

Authors:  M R Lewis; P W Callas; N S Jenny; R P Tracy
Journal:  Thromb Haemost       Date:  2001-12       Impact factor: 5.249

2.  FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse.

Authors:  Elliot D Rosen; Dave Gailani; Francis J Castellino
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

3.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.

Authors:  S R Poort; F R Rosendaal; P H Reitsma; R M Bertina
Journal:  Blood       Date:  1996-11-15       Impact factor: 22.113

4.  Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.

Authors:  Christoph Merlo; Walter A Wuillemin; Maurice Redondo; Miha Furlan; Irmela Sulzer; Johanna Kremer-Hovinga; Bernd R Binder; Bernhard Lämmle
Journal:  Atherosclerosis       Date:  2002-04       Impact factor: 5.162

5.  Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

Authors:  T W Meade; S Mellows; M Brozovic; G J Miller; R R Chakrabarti; W R North; A P Haines; Y Stirling; J D Imeson; S G Thompson
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

6.  Robust variance estimation for the case-cohort design.

Authors:  W E Barlow
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

7.  Fibrinogen and risk of cardiovascular disease. The Framingham Study.

Authors:  W B Kannel; P A Wolf; W P Castelli; R B D'Agostino
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

8.  Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.

Authors:  Simone J H Wielders; Suzette Béguin; H Coenraad Hemker; Theo Lindhout
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-08       Impact factor: 8.311

9.  Fibrinogen as a risk factor for stroke and myocardial infarction.

Authors:  L Wilhelmsen; K Svärdsudd; K Korsan-Bengtsen; B Larsson; L Welin; G Tibblin
Journal:  N Engl J Med       Date:  1984-08-23       Impact factor: 91.245

10.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

View more
  48 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

2.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 3.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

4.  Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice.

Authors:  Philberta Y Leung; Sawan Hurst; Michelle A Berny-Lang; Norah G Verbout; David Gailani; Erik I Tucker; Ruikang K Wang; Owen J T McCarty; András Gruber
Journal:  Transl Stroke Res       Date:  2012-09       Impact factor: 6.829

5.  Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.

Authors:  Guy L Reed; Aiilyan K Houng; Dong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

6.  Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Kristen M George; Duke Appiah
Journal:  Atherosclerosis       Date:  2015-09-10       Impact factor: 5.162

Review 7.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

9.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

10.  Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.

Authors:  N C Olson; S Butenas; L A Lange; E M Lange; M Cushman; N S Jenny; J Walston; J C Souto; J M Soria; G Chauhan; S Debette; W T Longstreth; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2015-09-14       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.